Jaguar Animal Health Inc. filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it is valued up to $70 million. The company will list its common stock on the Nasdaq Capital Market under the symbol JAGX when it begins trading.

The underwriters for the offering are BMO Capital Markets, Roth Capital Partners and Guggenheim Securities.

Jaguar is an animal health company with its focus being in gastrointestinal products for companion and production animals. Canalevia is its lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Neonorm is the lead non-prescription product to address the symptoms of watery diarrhea in pre-weaned dairy calves.

Jaguar has seven investigational new animal drug applications on file with the U.S. Food and Drug Administration (FDA) and it intends to develop species-specific formulations of Neonorm in six additional target species.

READ ALSO: Calithera Files for IPO to Fund Cancer Tumor Therapy Projects

Neonorm has a planned launch in the United States by the end of 2014. The additional formulations of Neonorm for other animal species are expected to launch in the beginning of 2015.

Jaguar’s goal is to become a leading animal health company that services both companion and production animal markets. The company plans to achieve this by leveraging its gastrointestinal knowledge, experience and intellectual property to develop a line of products across multiple market channels.

The net proceeds from this offering are planned to be allocated as such (all values are approximate):

• $4.5 million for clinical studies related to Canalevia
• $3.5 million for clinical studies related to prescription drug products for companion animals
• $3.0 million for studies and registration activities outside the United States related to Neonorm
• $2.0 million for the costs of developing other species-specific formulations
• $10.0 million for establishing manufacturing capability

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.